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Summary
Epidermolysis bullosa with pyloric atresia (EB-PA), an
autosomal recessive genodermatosis, manifests with ne-
onatal cutaneous blistering associated with congenital
pyloric atresia. The disease is frequently lethal, but non-
lethal cases have also been reported. Expression of the
a6b4 integrin is altered at the dermal-epidermal base-
ment-membrane zone; recently, mutations in the corre-
sponding genes (ITGA6 and ITGB4) have been disclosed
in a limited number of patients, premature termination
codons in both alleles being characteristic of lethal var-
iants. In this study, we have examined the molecular
basis of EB-PA in five families, two of them with lethal
and three of them with nonlethal variants of the disease.
Mutation analysis disclosed novel lesions in both ITGB4
alleles of each proband. One of the patients with lethal
EB-PA was a compound heterozygote for premature
termination–codon mutations (C738X/4791delCA),
whereas the other patient with a lethal variant was ho-
mozygous for a missense mutation involving a cysteine
residue (C61Y). The three nonlethal cases had missense
mutations in both alleles (C562R/C562R, R1281W/
R252C, and R1281W/R1281W). Immunofluorescence
staining of skin in two of the nonlethal patients and in
one of the lethal cases was positive, yet attenuated, for
a6 and b4 integrins. These results confirm that ITGB4
mutations underlie EB-PA and show that missense mu-
tations may lead to nonlethal phenotypes.
Received July 6, 1998; accepted for publication August 18, 1998;
electronically published October 27, 1998.
Address for correspondence and reprints: Dr. Jouni Uitto, Depart-
ment of Dermatology and Cutaneous Biology, Jefferson Medical Col-
lege, 233 South 10th Street, Suite 450, Bluemle Life Sciences Building,
Philadelphia, PA 19107. E-mail: Jouni.Uitto@mail.tju.edu
∗ Permanent affiliation: DNA and Chromosome Laboratory, Divi-
sion of Diagnostic Services, Kuopio University Hospital, Kuopio,
Finland.
 1998 by The American Society of Human Genetics. All rights reserved.
0002-9297/98/6305-0014$0200
Introduction
Epidermolysis bullosa with pyloric atresia (EB-PA;MIM
226730) is a recessively inherited genodermatosis man-
ifesting at birth or shortly thereafter, with blistering of
the skin and mucous membranes and with associated
congenital gastrointestinal abnormalities, including
esophageal, pyloric, or duodenal atresia (Nazarro et al.
1990; Fine et al. 1991; Lestringant et al. 1992). Clini-
cally, both lethal and nonlethal variants have been rec-
ognized, the lethal forms resulting in the demise of the
affected individuals usually within a few weeks or
months of the postnatal period; in nonlethal variants the
clinical severity of the skin involvement often tends to
improve with age. The patients often demonstrate nail
dystrophy and dental anomalies, including enamel hy-
poplasia. Ultrastructurally, the skin lesions are charac-
terized by blister formation at the level of the lamina
lucida or at the lamina lucida/basal keratinocyte inter-
face, associated with hypoplastic hemidesmosomes
(Niessen et al. 1996; Pulkkinen et al. 1998b). Conse-
quently, this disease has been traditionally classified as
a form of junctional epidermolysis bullosa (EB), but re-
cent reclassification of various forms of EB, based on
molecular evaluation of these patients, has suggested
that EB-PA is a hemidesmosomal variant (Uitto et al.
1997; Pulkkinen and Uitto 1998).
Initial clues to the underlying molecular defects in EB-
PA were suggested by the demonstration of absent or
reduced expression of the a6 and/or b4 integrin in the
skin of these patients, by immunofluorescence micros-
copy using antibodies specific to these integrin epitopes
(Gil et al. 1994; Brown et al. 1996; Shimizu et al. 1996).
As a result, the corresponding genes, ITGA6 and ITGB4,
encoding the a6 and b4 integrin polypeptides, respec-
tively, were considered as candidate genes for mutations
in EB-PA. In accordance, we and others have recently
disclosed distinct mutations in both of these genes in EB-
PA patients representing nine families. In seven families,
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Table 1
Diagnostic Features and Mutation Analysis in Patients with EB-PA
Family
Proband
Age (Sex) Clinical Features
Disease
Variant
Ultrastructural Features/
Immunofluorescence ITGB4 Mutations
Consequences
of Mutations
1 7 years (F) PA at birth; skin in-
volvement noted at
age ∼2 years
Nonlethal Hypoplastic hemidesmo-
somes without distinct in-
ner and outer plaques, re-
duced expression of a6
and b4 integrin epitopes
C562R/C562R Missense/missense
2 Newborn (M) PA at birth, general-
ized blistering and
erosions of the skin
at birth
Lethal Hypoplastic hemidesmo-
somes, tissue separation
at the level of plasma
membrane, reduced stain-
ing with antibodies
against a6 and b4
integrins
C738X/4791delCA PTC/PTC
3 10 mo (M) Antral atresia at birth,
blisters on fingers
and toes at end of
1st wk of life
Nonlethal R1281W/R252C Missense/missense
4 Newborn (F) PA at birth, extensive
blistering within 1st
wk of life
Lethal Absence of hemidesmosomes C61Y/C61Y Missense/missense
5 4 mo (M) PA at birth, blisters on
the sacral area
noted at age ∼3 mo
Nonlethal b4 integrin expression re-
duced, a6 integrin normal
R1281W/R1281W Missense/missense
the mutations were present in the ITGB4 gene, whereas
in two of them mutations in the ITGA6 gene were found
(Vidal et al. 1995; Pulkkinen et al. 1997a, 1997b, 1998a,
1998b; Ruzzi et al. 1997; Takizawa et al. 1997). Eight
of the nine probands in whom the mutations have been
disclosed thus far have a lethal phenotype, and the ma-
jority of mutations resulted in a premature termination
codon (PTC) for translation (see Pulkkinen and Uitto
1998). In one case with lethal EB-PA, a combination of
a PTC-causing mutation (120delTG) and a missensemu-
tation (C245G) was noted (Pulkkinen et al. 1998b). On
the other hand, compound heterozygosity for a missense
(L156P) and a nonsense (R554X) mutation in the b4
integrin gene was shown to underlie the relatively mild,
nonlethal phenotype (Pulkkinen et al. 1998a). These ob-
servations suggested, therefore, that, in general, PTC
mutations in both alleles predict a lethal phenotype,
whereas a missense mutation in the second allele may
signify a milder phenotype with a nonlethal outcome.
In this study, we have examined the molecular basis of
EB-PA in five patients, two presenting a lethal phenotype
and three presenting a nonlethal phenotype.
Subjects and Methods
Clinical and Genetic Features
Family 1.—The proband of this family was a 7-year-
old female who was the third child from a consanguin-
eous union, the parents being first cousins of Turkish
extraction. The proband manifested at birth with PA,
which was surgically corrected at age 4 d. Fragility of
the skin was noted during the 2d year of life, and at age
7 years the child had very localized blistering, affecting
primarily the extremities and perioral areas of the skin,
associated with nail dystrophy and enamel pitting of the
teeth (table 1 and fig. 1).
Immunoepitope mapping of the skin, using a battery
of monospecific antibodies recognizing cutaneous base-
ment-membrane zone (BMZ) epitopes revealed reduced
expression of both a6 and b4 integrin subunits at the
roof of the blister cavity, as well as on sweat glands, in
comparison with normal control skin (fig. 2). In contrast,
laminin 5 staining using the monoclonal antibody GB3
showed essentially normal results for the blister floor, in
comparison with control skin (fig. 2G and H).
Transmission electron microscopy revealed the pres-
ence of hypoplastic hemidesmosomes without distinct
inner and outer plaques. Most hemidesmosomes ap-
peared to be connected to the intermediate-filament net-
work.
Family 2.—The proband of this family, a newborn
male, was the second child of nonconsanguineous par-
ents. He had a 3-year-old sister who was clinically un-
affected. At birth, the proband exhibited blistering that
was confined to the fingers, ankles, and feet, at the sites
of mechanical trauma, as well as in the oral mucosa.
Despite successful gastroduodenostomy at age 13 d to
repair the pyloric atresia, he was unable subsequently
to be weaned from nasogastric tube feeding, because of
a secondary swallowing dysfunction that resulted in as-
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Figure 1 Clinical features of proband of family 1. A, Trauma-induced localized blistering of right hand. B, Dystrophy of toenails. Note
that the left big toenail had additional onychomycosis. C, Blistering of lips, as well as dental anomalies with enamel hypoplasia and caries.
piration. He failed to thrive and died during the 3d mo
of the postnatal period.
Transmission electron microscopy revealed hypoplas-
tic hemidesmosomes, and tissue separation was noted at
the level of the plasma membrane (fig. 3). Immunohis-
tochemical staining of unaffected skin, with a battery of
monoclonal antibodies to BMZ antigens, revealed nor-
mal staining intensity and distribution for laminin 5;
collagen types IV, VII, and XVII; BP230; and plectin/
HD1. However, staining for the a6 and b4 integrin ep-
itopes was positive but reduced (fig. 4).
Family 3.—The proband of this family was a 10-mo-
old male who, shortly after birth, was diagnosed as hav-
ing antral atresia, which was immediately corrected by
surgery. The parents were of Bangladeshi ethnic origin
and were not known to be related.
At the end of the 1st wk of life, the patient developed
blisters on his fingers, toes, and scalp. He has continued
to develop blisters, but their frequency has lessened dur-
ing the 1st year of life. The mother had three earlier
pregnancies; the first and the third resulted in healthy
males. The second pregnancy resulted in a male, deliv-
ered at home, with congenital aplasia cutis on the arm.
This patient also had clinical signs of gastrointestinal
atresia, but no surgical intervention was attempted, and
the patient died at age 6 d.
Family 4.—The proband in this family was a newborn
female who had congenital PA, which was not corrected,
and she developed extensive blistering shortly after birth.
Transmission electron microscopy of the skin revealed
hypoplastic hemidesmosomes, but immunofluorescence
analysis was not done. The newborn died at age 2 wk,
from complications of the disease.
Family 5.—The proband in this family is a male infant
of first-cousin Orthodox Jewish parents. He had PA at
birth and developed nail dystrophy at age 2 mo. At age
3 mo, he developed blistering of the skin, as well as
severe nephrotic syndrome. Indirect immunofluores-
cence staining of cryosections containing dermis (epi-
dermis was lost) from the proband revealed positive but
reduced staining of sweat glands for b4 integrin, whereas
a6 integrin, laminin 5, and the 230-kD bullous pem-
phigoid antigens were normally expressed.
Collectively, the clinical material consisted of five
patients with diagnostic features of EB-PA. Three of
them (patients 1, 3, and 5) had a nonlethal phenotype,
whereas two of them (patients 2 and 4) died during the
early postnatal period, from complications of the disease
(table 1).
Immunofluorescence and Electron Microscopy
The distribution of antigens in skin samples was an-
alyzed by microscopic examination of cryostat sections
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Figure 2 Indirect immunofluorescence staining of skin of pro-
band of family 1 and of normal control skin. Antibodies to b4 integrin
(A–D) revealed attenuated staining at the roof of a blister (A) and of
the sweat glands (C) of the patient, compared with staining of the
dermo-epidermal junction (B) and sweat glands (D) in normal control
skin. Staining with antibodies to a6 integrin showed a slightly atten-
uated reaction in the patient’s skin (E), compared with that of the
control (F). Laminin 5 staining was found in the blister base of the
patient’s skin (G); the arrowheads indicate the blister roof. Normal
control skin stained with antibodies to laminin 5 is shown for com-
parison (H).
stained either by the indirect immunofluorescence
method using FITC-conjugated secondary antibodies or
by the indirect immunoperoxidase method described
elsewhere (Brown et al. 1996).
Skin biopsies were prepared for electron microscopy,
according to standard protocols. In brief, samples were
placed in half-strength Karnovsky’s fixative, postfixed in
osmium tetraoxide, en bloc–stained in uranyl acetate,
dehydrated by graded ethanol and propylene oxide, and
embedded into epoxy resin. Ultrathin sections were
stained sequentially with phosphotungstic acid, uranyl
acetate, and lead citrate and were viewed by means of
a Philips 420 STEM operated at 60 kV.
Characterization and Verification of Mutations
Mutation-detection strategy included PCR amplifi-
cation of each exon and of the flanking intronic
sequences of the ITGB4 gene in each family, followed
by heteroduplex scanning of the PCR products, as de-
scribed elsewhere (Pulkkinen et al. 1998b). Specifically,
the following primers were used to amplify ITGB4 exons
4, 8, 14, 18, 31, and 36, by use of total genomic DNA
isolated from peripheral blood as the template: E4-L, 5′-
TCGGGAATAGCTGGTGGAAA-3′; and E4-R, 5′-
CCCATAAATAGCCAGGCTGA-3′; E8-L, 5′-GCC-
GTGATGCGTGTCAGCAG-3′; and E8-R, 5′-CCA-
TGGACCCCCTACCTTGA-3′; E14-L, 5′-AGGTGG-
GCAGCCTGGACTAC-3′; and E14-R, 5′-TAGGAG-
GGGGCACCAGTGAG -3′; E18-L, 5′-AGCTCGGTG-
GGGAGGACAGG-3′; and E18-R, 5′-AGAACT-
CAGGCGGGGCTGG-3′; E31-L, 5′-CTGTGTCAG-
GGGTGGTGTTG-3′; and E31-R, 5′-CCACGATAG-
GGATGTCAGGG-3′; E36-L, 5′-GGGGGCAGCACT-
GTGACTCC-3′; and E36-R, 5′-AGGGACTTGGGT-
GGGTTCCT-3′.
The PCR reactions were performed in a total volume
of 50 ml containing 1 # PCR buffer, either 1.25 U of
Taq polymerase (Qiagen) (for exons 4, 8, 14, 31, and
36) or Expand High Fidelity PCR System (Boehringer
Mannheim) (for exon 18), 4% dimethylsulfoxide, 12.5
pmol of each primer, and 200 ng of genomic DNA. The
amplification conditions were as follows: 5 min at 95C
for one cycle, followed by 38 cycles of 45 s at 95C, 45
s at the annealing temperature (60C for exons 4, 8, and
31; 62C for exon 18; and 64C for exons 14 and 36),
and 45 s at either 72C (Taq polymerase; Qiagen) or
68C (Expand High Fidelity Enzyme; Boehringer
Mannheim). The PCR products were analyzed by con-
formation-sensitive gel electrophoresis (CSGE), as de-
scribed elsewhere (Ganguly et al. 1993). All PCR
products demonstrating heteroduplexes were directly se-
quenced by an automated DNA sequencer (ABI).
In each family, the verification of the mutation was
performed on the basis of the PCR products representing
the proband and his or her immediate family members,
by use of either restriction-endonuclease digestions (BsrI
for family 1, SfaNI for family 2, NarI and BsaWI for
family 3, and BsaWI for family 5) or allele-specific oli-
gonucleotide hybridization (ASO) (for families 2 and 4).
1380 Am. J. Hum. Genet. 63:1376–1387, 1998
Figure 3 Transmission electron microscopy of skin. A–C, Proband of family 2. D, Unrelated normal control. Basal keratinocytes have a
reduced number of hypoplastic hemidesmosomes (A and C [arrows]). There are perinuclear arrays of keratin filaments, but the abundance of
keratin filaments is diminished in the basal compartment of the cell. Electron-dense material along the basal plasma membrane suggests the
presence of incomplete hemidesmosomes (C [arrowheads]). Normal hemidesmosomes are shown in control skin (D [arrow]). Separation of the
epidermis from the basement membrane left fragments of the basal keratinocyte associated with the basal lamina (B [arrow]). (Scale bars are
1 mm [A and B] and 500 nm [C and D].)
The allele-specific oligomer primers for verification of
mutation C61Y in family 4 were as follows: wild type,
5′-CCGGCGCTGCAACACCC-3′; mutant, 5′-CCGGC-
GCTACAACACCCA-3′.
For verification of mutation 4791delCA in family 2,
the ASO primers were as follows: wild type, 5′-
ACATCTCTCAGAGTGAGCT-3′; mutant, 5′-CCACA-
TCTCTGAGTGAGCT-3′.
The oligomers were 5′ end-labeled with g[32P]-dATP.
The PCR products were dotted onto nylon filters (Zeta
probe; Bio-Rad), immobilized by UV cross-linking, and
hybridized with radioactive oligomers at 37C, accord-
ing to the manufacturer’s recommendations. The filters
were washed to the final stringency of 0.2# SSPE, 0.1%
SDS, at the melting temperatures of the oligomers. The
filters were exposed to x-ray film.
Results
Identification and Verification of Mutations
The mutation screening in each proband and his or
her immediate family members was performed as de-
scribed in Subjects and Methods, starting with PCR am-
plification of each exon of ITGB4, followed by hetero-
duplex analysis on CSGE gels and direct sequencing of
the PCR products showing heteroduplexes (Pulkkinen
et al. 1998b). This strategy is illustrated in figure 5.
Family 1.—Screening of ITGB4 for mutations in this
family revealed heteroduplex bands in the case of exon
14, in DNA from both parents. Direct nucleotide se-
quencing of the corresponding PCR products revealed
that both parents were heterozygous for a CrT substi-
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Figure 4 Altered a6b4 integrin expression in EB-PA skin from
the proband of family 2. Immunoperoxidase-labeled cryostat sections
of EB-PA patient’s skin (a, c, and e) and of normal control skin (b, d,
and f) were stained for integrin subunits, with either anti-b4 (clone
3E1; a–d) or anti-a6 (clone GoH3; e and f) monoclonal antibodies.
Tissue sections in panels c and d were extracted with 0.5% Triton X-
100 prior to formaldehyde fixation. Staining intensity for both integrin
subunits was reduced in the EB-PA patient’s skin (a and e) vs. that in
the normal control skin (b and f) but remained polarized predomi-
nantly to the basal-cell surface. A major fraction of the integrin b4
subunit could be removed in the EB-PA patient’s skin (c), but not in
the normal control skin (d), by Triton X-100 extraction, suggesting
an altered structural organization for this integrin in EB-PA. Similar
results were obtained with staining with several other anti-a6 and b4
integrin subunit-specific monoclonal antibodies.
tution at nucleotide position 1684, whereas the proband
was homozygous for this transition (table 1). This nu-
cleotide substitution resulted in a change from cysteine
(TGT) to arginine (CGT), at amino acid position 562
(C562R) within the third cysteine-rich repeat of the ex-
tracellular domain of b4 integrin polypeptide. This nu-
cleotide substitution also abolished a restriction site for
BsrI, which was used to verify the presence of this mu-
tation in the parents’ (heterozygous) and proband’s (ho-
mozygous) DNA. Screening of 100 chromosomes from
normal, healthy controls by BsrI digestion demonstrated
the absence of C562R, suggesting that it was a patho-
genetic mutation rather than a common polymorphism.
Family 2.—In this family, scanning of the ITGB4 gene
by CSGE revealed a heteroduplex band when exon 18
was amplified from the proband’s and the father’s DNA,
whereas the mother’s DNA revealed the presence of a
homoduplex band only (fig. 5A, upper panel). Direct
sequencing of the corresponding PCR products revealed
the presence of a heterozygous CrA nucleotide substi-
tution at nucleotide position 2214, which changed a co-
don for cysteine (TGC) to a stop codon (TGA), at amino
acid position 738 (fig. 5B). This nucleotide substitution
created a new restriction site for SfaNI; digestion of the
PCR products confirmed that the proband and the father
were heterozygous for this mutation, whereas the
mother’s DNA showed the presence of the wild-type
allele only (fig. 5C).
Further scanning of the ITGB4 revealed heteroduplex
bands in exon 36 in the proband’s and the mother’s
DNA, whereas the father’s DNA revealed the presence
of a homoduplex band only (fig. 5A, lower panel). Direct
sequencing of the PCR products revealed the pres-
ence of a 2-bp deletion at nucleotide position 4791
(4791delCA), which created a PTC for translation, 77
nucleotides downstream from the site of deletion (fig.
5D). The presence of this genetic lesion in the proband’s
and the mother’s DNA was verified by ASO, which also
revealed that the father did not have this mutation (fig.
5E). Thus, the proband in this family was a compound
heterozygote for ITGB4 mutations, C738X/4791delCA,
both mutations causing PTCs.
Family 3.—In this family, heteroduplexes were noted
with PCR products spanning exons 31 and 39 of ITGB4
when DNA from the proband and the mother was ex-
amined, whereas the father’s DNA revealed homoduplex
bands only. Sequencing of the PCR products correspond-
ing to exon 39 revealed a GrC nucleotide change at
nucleotide position 25 in intron 38 (5213–25G r C),
which was a polymorphism recognized by restriction
enzyme BglI (see table 2). Sequencing of the PCR prod-
uct spanning exon 31 and flanking intronic sequences
revealed a CrT transition at nucleotide position 3841,
which resulted in an amino acid change from an arginine
(CGG) to a tryptophan (TGG), at amino acid position
1281 (R1281W; table 1). This nucleotide change abol-
ished a restriction-enzyme site for BsaWI, which was
used for verification of the inheritance of the mutation
from the mother to the proband. This nucleotide change
was not noted either in the father’s DNA or in 120
chromosomes from unrelated healthy control individu-
als, suggesting that it is a pathogenetic mutation rather
than a polymorphism.
No other heteroduplexes were found in ITGB4, and
results of scanning of the ITGA6 gene by CSGE (Pulk-
kinen et al. 1997a) was negative. Subsequently, all other
PCR products corresponding to the entire coding se-
quence of ITGB4 from the proband were sequenced di-
rectly. This revealed two other nucleotide changes. Exon
34 had a silent GrC transversion at nucleotide position
4521, which was recognized by restriction enzymes
BstNI and EcoRII (see table 2). A CrT transition was
noted in exon 8, at nucleotide position 754, which re-
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Figure 5 Mutation analysis and prenatal testing in family 2. A, CSGE analysis of ITGB4, which reveals heteroduplex bands in father’s
(lane F) and proband’s (lane P) PCR products spanning exon 18 (upper panel) and in mother’s (lane M) and proband’s PCR products spanning
exon 36 (lower panel). B, Direct nucleotide sequencing of the PCR product from the proband, spanning exon 18, revealed a heterozygous CrA
transversion, which resulted in substitution of a codon for cysteine (TGC) by a stop codon (TGA); the mutation was designated “C738X”
(upper panel). C, Verification of inheritance of mutation, by use of restriction enzyme SfaNI, which recognized the site of themutation. Specifically,
the mutant allele was digested to 144- and 113-bp bands, whereas the normal allele, corresponding to the 257-bp band, resisted digestion. The
results showed that the father and the proband were heterozygous carriers of the mutation whereas the mother harbored the normal alleles in
both chromosomes. D, Direct nucleotide sequencing of PCR product from proband, spanning exon 36, revealing a heterozygous 2-bp deletion
(CA) at nucleotide position 4791 (upper panel), compared with the normal sequence (lower panel). E, Verification of inheritance of mutation
4791delCA , by allele-specific oligomer hybridization as described in Subjects and Methods. Specifically, the PCR products from the mother
and the proband hybridized both to wild-type (WT) and to mutant (M) oligomers, indicating that these individuals are heterozygous for this
mutation, whereas the father’s PCR product hybridized to the normal oligomer only, indicating that he is homozygous for the normal sequence.
In a subsequent pregnancy, the family requested prenatal testing of the fetus at risk for EB-PA. DNA from amniotic cells was amplified for
exons 18 and 36, and the PCR products were studied for the mutations C738X and 4791delCA, by use of SfaNI digestion and ASO, respectively.
The SfaNI digestion revealed that the fetus had inherited the paternal mutation (C; PND) and a normal maternal allele (E; PND). Thus, the
fetus was predicted to be an unaffected carrier of the paternal mutation.
sulted in the change of a codon for arginine (CGC) to
a codon for cysteine (TGC), at amino acid position 252
(R252C). This nucleotide change abolished a restriction-
enzyme site for NarI, which was used to verify the in-
heritance of the transition from the father to the pro-
band. Furthermore, theNarI screening demonstrated the
absence of this nucleotide change not only in the ma-
ternal DNA but also in 110 chromosomes from unre-
lated healthy control individuals, suggesting that R252C
is the paternally inherited pathogenetic mutation.
Family 4.—Screening of the ITGB4 gene for mutations
in this family revealed similar heteroduplexes when the
PCR products spanning exon 4 and flanking intronic
sequences in both parents were analyzed by CSGE,
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Table 2
Nucleotide Variations in the ITGB4 Gene
LOCATION
NUCLEOTIDE
POSITION
NUCLEOTIDE
VARIANT
RESTRICTION-
ENZYME SITE(S)
ALLELIC
FREQUENCIESaMajor Minor
Exon 7 579 T (Pro) C (Pro) StyI, BanII Not determined
Exon 13 1544 G (Arg) A (His) EagI, NcoI .932/.068
Intron 25 296261 T G MspI Not determined
Intron 27 331746 C T HphI .900/.100
Intron 28 347421 C T PalI/HaeIII/BsuRI .635/.365
Intron 28 347478 G A StyI .875/.125
Exon 30 3730 G (Pro) A (Pro) ) .990/.010
Exon 34 4521 G (Pro) C (Pro) BstNI/EcoRII .550/.450
Intron 34 4558146 ACAT deletion ) .850/.150
Exon 38 5097 G (Pro) A (Pro) Cac8 I .987/.013
Intron 38 521325 G C BglI .600/.400
Intron 39 537815 A G DrdI .989/.011
Exon 41 5495 C (Pro) T (Leu) ) .690/.310
Exon 41 5653 T C MaeII Not determined
a In 50 unrelated healthy controls.
whereas the proband showed a homoduplex band only.
Sequencing of the PCR products demonstrated that both
parents were heterozygous for a GrA transition at nu-
cleotide position 182, which resulted in the change of a
codon for cysteine (TGC) to a codon for tyrosine (TAC),
at amino acid position 61 (C61Y). The proband was
shown to be homozygous for this nucleotide change.
Since this nucleotide substitution could not be recog-
nized by any restriction endonuclease, verification of this
transition in this family, as well as verification of its
absence in 100 chromosomes of unrelated healthy in-
dividuals, was performed by ASO hybridization, which
suggested that it was a pathogenetic mutation rather
than a polymorphism.
Family 5.—In this family, heteroduplex scanning of
the parents’ DNA revealed identical heteroduplex bands
when the PCR amplification products corresponding
to exon 34 of ITGB4 were examined by CSGE. Direct
sequencing of the PCR products revealed a CrT tran-
sition at nucleotide position 3841 within exon 31,
which changed a codon for arginine (CGG) to a codon
for tryptophan (TGG), a mutation designated as
“R1281W.” The proband was shown by sequence anal-
ysis to be homozygous for this mutation (R1281W/
R1281W), and these results were confirmed by BsaWI
restriction-enzyme digestion (see case 3).
DNA-Based Prenatal Testing in Family 2
As indicated above, the proband of family 2, who had
died prior to being tested, was found to be a compound
heterozygote for ITGB4 mutations, C738X/4791delCA,
present in exons 18 and 36, respectively. At the time of
mutation analysis, the parents requested prenatal testing
of a subsequent pregnancy, which was considered to be
at risk for recurrence of EB-PA. Sequencing as well as
SfaNI digestion and ASO-analysis of PCR products
spanning exons 18 and 36 from DNA isolated from
amniotic cells at the 15th wk of gestation revealed that
the fetus was a carrier of the paternal mutation, C738X
(see fig. 5). However, the fetus did not have the maternal
mutation, predicting a phenotypically normal child, and
a healthy baby was born at term.
Identification of Novel Polymorphisms in ITGB4
During the search for pathogenetic mutations in the
ITGB4 gene in these five families, as well as in those
that we have reported elsewhere (Pulkkinen et al. 1997a,
1998a, 1998b), a number of polymorphisms were de-
tected (table 2). Many of these polymorphisms change
a restriction-enzyme site, thus allowing expedient screen-
ing of the general population. Of these polymorphisms,
two changed the corresponding amino acid (R515H in
exon 13 and P1832L in exon 41). These amino acid
substitutions were found in the general population (see
table 2), indicating that they are normal polymorphisms.
The remainder of the polymorphisms were either silent
exonic or intronic. Also, a biallelic ACAT-deletion poly-
morphism was disclosed in intron 34. These polymor-
phisms will assist in further genetic linkage analysis
when the ITGB4 gene, which has been mapped to chro-
mosomal locus 17q25 (Bhalerao et al. 1997), is exam-
ined in the context of families with EB-PA.
Discussion
In this study, we have identified novel mutations in
the ITGB4 gene in five families with EB-PA. Of the five
probands, three were homozygous (C562R/C562R,
C61Y/C61Y, and R1281W/R1281W) and one was
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Figure 6 Schematic illustration of b4 integrin polypeptide and locations of all ITGB4 mutations disclosed thus far. The PTC mutations
are drawn above the molecule, and the missense mutations or a splicing mutation resulting in in-frame deletion are shown below the molecule.
ECD  extracellular domain; TM  transmembrane domain; ICD  intracellular domain.
compound heterozygous (R1281W/R252C) for novel
missense mutations. The fifth proband was a compound
heterozygote for two PTC mutations (C738X/
4791delCA). Previously, either PTC mutations in both
alleles or a PTC mutation in one allele and a missense
mutation in the other allele have been detected in the
ITGB4 gene in seven families with EB-PA (fig. 6; Pulk-
kinen and Uitto 1998). In addition, homozygous non-
sense mutations in the ITGA6 gene encoding the a6
subunit of the a6b4 integrin have been reported in two
families with EB-PA (Pulkkinen et al. 1997b; Ruzzi et
al. 1997). In both cases, the phenotype was lethal, in-
distinguishable from those with nonsense mutations in
both alleles of the ITGB4 gene.
The repertoire of mutations disclosed thus far suggests
that the presence of PTCs in both alleles, either in a
homozygous or in a compound-heterozygous state, will
result in a lethal phenotype. However, the presence of a
missense mutation, either in one allele in combination
with a PTC mutation or in both alleles, could predict a
more variable and occasionally milder nonlethal phe-
notype. For example, in a previous study a leucine-to-
proline substitution in the amino acid position 156 of
b4 integrin polypeptide, in combination with a PTC mu-
tation (R554X), resulted in a mild clinical phenotype,
whereas a PTC mutation combined with C245G mis-
sense mutation resulted in a lethal condition (Pulkkinen
et al. 1998a, 1998b). In the present study, the homo-
zygous cysteine substitution mutation C562R, as well as
the homozygous and compound-heterozygous missense
mutations R1281W/R1281W and R1281W/R252C,
were found in nonlethal variants of EB-PA. In fact, the
skin involvement in some of these patients was so mild
that blistering was not noted until the age of ∼2 years,
as in case 1. This raises the intriguing possibility that
some patients with PA but without evidence of skin blis-
tering may harbor mutations in the a6b4 integrin genes.
The patient with the homozygous missense mutation
C61Y died at age !2 wk, because of extensive skin in-
volvement as well as complications of PA that was not
operated on. Thus, it remains unclear whether this ho-
mozygous mutation would have ultimately resulted in a
lethal or nonlethal condition if the pyloric abnormalities
would have been corrected.
The expression of a6b4 integrin was studied by im-
munohistochemistry in the skin of three patients (cases
1, 2, and 5) with lethal and nonlethal phenotypes, re-
spectively. Interestingly, this work reports, for the first
time, clearly positive, although markedly reduced, ex-
pression of the a6 and the b4 integrin epitopes in a
patient (case 2) with a lethal phenotype and PTC mu-
tations in both alleles. Triton X-100 extraction removed
most of the immunoreactive material, suggesting an al-
tered structure of the b4 polypeptide containing the ep-
itope. In this patient, the mutation R738X resides within
the intracellular domain just adjacent to the transmem-
brane segment and is predicted, therefore, to result in
deletion of the entire intracellular domain of the b4 in-
tegrin polypeptide. In vitro transfection studies have
shown that tailless b4 integrin affects hemidesmosome
assembly but that ligand binding is preserved (Spinardi
et al. 1995). The construct used in the latter studies was
137 amino acids longer than the putative polypeptide
corresponding to the allele containing the R738X mu-
tation. The other mutation, 4791delCA, is predicted to
delete the region spanning the last 278 amino acids in
the intracellular domain, which has been shown to in-
teract with the 180-kD bullous pemphigoid antigen (Aho
and Uitto 1998). Thus, the extracellular domain is re-
tained in both alleles, suggesting the possibility of a6b4
Pulkkinen et al.: ITGB4 Mutations in EB-PA 1385
dimer formation and a positive signal on indirect im-
munofluorescence. It should be noted, however, that the
expression of the truncated polypeptide may be signif-
icantly reduced because of nonsense-mediated decay of
the corresponding mRNA transcripts (Cui et al. 1995).
In nonlethal cases with homozygous C562R and
R1281W mutations, the a6b4 expression was clearly
detectable yet attenuated. A similar situation has been
described elsewhere, in a mild EB-PA case who was a
compound heterozygote for a PTC mutation and a mis-
sense mutation (R554X/L156P). In contrast, the ex-
pression of a6b4 was absent in the skin of another pa-
tient with compound heterozygosity for missense and
PTC mutations (120delTG/C245G) resulting in a lethal
phenotype. Thus, it appears that the type and location
of the missense mutations influence the expression levels
of the a6b4 integrin as well as the clinical phenotype.
It should be noted that two homozygous missense mu-
tations (C562R and C61Y) disclosed in this study both
affect cysteine residues within the extracellular domain
of the b4 integrin polypeptide (see fig. 6). It is expected
that loss of these cysteine residues could potentially in-
terfere with the formation of intra- or interchain disul-
fide bonds, with subsequent changes in the conformation
and/or ligand-binding affinity of this protein. At the
same time, one of the missense mutations, R252C, cre-
ated a new cysteine residue, which may result in mis-
pairing of the cysteines in the extracellular domain.
The intracellular domain of the b4 integrin has been
shown to interact with other hemidesmosomal compo-
nents of basal keratinocytes, including plectin and the
180-kD bullous pemphigoid antigen (Borradori et al.
1997; Niessen et al. 1997; Sanchez-Aparicio et al. 1997;
Aho and Uitto 1998). It is conceivable, therefore, that
missense mutations such as R1281W, shown to be pres-
ent in the probands of families 3 and 5, could alter such
binding. In case of the proband of family 3, both mu-
tations were missense mutations, one affecting the in-
tracellular and the other one affecting the extracellular
domain of the b4 integrin (see fig. 6). Interestingly, in
this case the skin phenotype was particularly severe at
the early stages of postnatal life, but significant improve-
ment during the subsequent months was noted. In com-
parison, in the proband of family 5, who was homo-
zygous for the R1281W mutation, the skin problems
started at age 3 mo, together with nephrotic syndrome.
Since renal involvement is not a consistent clinical fea-
ture in EB-PA, the relationship between the nephrosis
and the b4 integrin mutation is not clear, especially since
b4 integrin has been reported not to be expressed in the
kidney (van Leusden et al. 1997).
In case of family 2, DNA-based prenatal testing was
performed by amniocentesis at the 15th wk of gestation.
The results indicated that the fetus was a heterozygous
carrier of the paternal mutation, and a phenotypically
unaffected child was predicted. This prediction was ful-
filled by the birth of a healthy child. This case attests to
the feasibility of DNA-based prenatal testing in severe
forms of EB, including the EB-PA variant. It should be
noted that such prenatal testing can be performed as
early as the 10th wk of gestation, with a chorionic villus
sample (Christiano et al. 1996, 1997).
In summary, we have identified a total of six novel
mutations in all 10 ITGB4 alleles of five patients affected
with EB-PA. The results indicate that missensemutations
in either the homozygous or the heterozygous state, in
addition to PTC mutations that previously have been
demonstrated in both alleles of the ITGA6 and ITGB4
genes, can lead to EB-PA. The involvement of two organ
systems—namely, the skin and the gastrointestinal
tract—can be explained by the fact that the a6b4 in-
tegrin is developmentally expressed in both of these tis-
sues and apparently plays a critical role in providing
stability to the association of the epithelial layers of the
underlying mesenchyme (Stepp et al. 1990; Sonnenberg
et al. 1991; Thorsteinsdo´ttir et al. 1995). This conclusion
is supported by the development of transgenic mice with
targeted ablation of either the a6 or the b4 integrin gene,
which results in both marked fragility of the skin and
congenital intestinal abnormalities reminiscent of those
noted in patients with EB-PA (Dowling et al. 1996; Geor-
ges-Labouesse et al. 1996; van der Neut et al. 1996).
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